These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 20883112)

  • 1. Use of aromatase inhibitors and bisphosphonates as an anticancer therapy in postmenopausal breast cancer.
    Mouridsen HT; Lønning P; Beckmann MW; Blackwell K; Doughty J; Gligorov J; Llombart-Cussac A; Robidoux A; Thürlimann B; Gnant M
    Expert Rev Anticancer Ther; 2010 Nov; 10(11):1825-36. PubMed ID: 20883112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing the risk of distant metastases in breast cancer patients: role of aromatase inhibitors.
    Del Mastro L; Clavarezza M; Venturini M
    Cancer Treat Rev; 2007 Dec; 33(8):681-7. PubMed ID: 17850976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women.
    Mouridsen HT; Robert NJ
    Eur J Cancer; 2005 Aug; 41(12):1678-89. PubMed ID: 16098456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
    Ingle JN
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.
    Winer EP; Hudis C; Burstein HJ; Wolff AC; Pritchard KI; Ingle JN; Chlebowski RT; Gelber R; Edge SB; Gralow J; Cobleigh MA; Mamounas EP; Goldstein LJ; Whelan TJ; Powles TJ; Bryant J; Perkins C; Perotti J; Braun S; Langer AS; Browman GP; Somerfield MR
    J Clin Oncol; 2005 Jan; 23(3):619-29. PubMed ID: 15545664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of third-generation aromatase inhibitors and tamoxifen in the adjuvant treatment of postmenopausal patients with hormone-dependent breast cancer: evidence based review.
    Poole R; Paridaens R
    Curr Opin Oncol; 2007 Nov; 19(6):564-72. PubMed ID: 17906453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
    Chlebowski RT
    Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reducing early recurrence with adjuvant aromatase inhibitors: what is the evidence?
    Dixon JM
    Breast; 2008 Aug; 17(4):353-60. PubMed ID: 18490163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen.
    Oyan B
    Med Hypotheses; 2011 Dec; 77(6):1028-30. PubMed ID: 21930348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should bisphosphonates be utilized in the adjuvant setting for breast cancer?
    Lipton A
    Breast Cancer Res Treat; 2010 Aug; 122(3):627-36. PubMed ID: 20490653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aromatase inhibitors and breast cancer.
    Miller WR
    Minerva Endocrinol; 2006 Mar; 31(1):27-46. PubMed ID: 16498362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging role of the new aromatase inhibitors in the treatment of breast cancer.
    Sulkes A
    Isr Med Assoc J; 2005 Apr; 7(4):257-61. PubMed ID: 15847208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A practical overview of aromatase inhibitors in postmenopausal women with hormone receptor-positive breast cancer.
    Younus J; Vandenberg TA
    Bull Cancer; 2005 Apr; 92(4):E39-44. PubMed ID: 15888383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary: optimal adjuvant endocrine therapy of postmenopausal breast cancer.
    Cunnick G; Mokbel K
    Int J Fertil Womens Med; 2005; 50(5 Pt 1):197-8. PubMed ID: 16468468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aromatase inhibitors in the treatment of early and advanced breast cancer.
    Joensuu H; Ejlertsen B; Lønning PE; Rutqvist LE
    Acta Oncol; 2005; 44(1):23-31. PubMed ID: 15848903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on aromatase inhibitors in breast cancer.
    Gould RE; Garcia AA
    Curr Opin Obstet Gynecol; 2006 Feb; 18(1):41-6. PubMed ID: 16493259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bisphosphonates: ready for use as adjuvant therapy of breast cancer?
    Theriault RL
    Curr Opin Obstet Gynecol; 2010 Feb; 22(1):61-6. PubMed ID: 19934757
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.